Compare AstraZeneca plc (AZN) vs Fabrinet (FN) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

FN trades at $474.64, up 0.75% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals despite positive fundamental trends, including 39% YoY revenue growth and expanding margins. Analyst consensus remains strongly bullish with a $733 price target, though valuation metrics appear elevated with a P/E of 41.48.

The outlook remains positive given FN's strategic position in AI optical supply chains and capacity expansion plans. Key risks include premium valuation, supply chain constraints, and technical weakness. The company's debt-free balance sheet and hyperscaler relationships provide stability amid growth execution challenges.